Search results
Emend is an antiemetic, a medicine that prevents nausea (feeling sick) and vomiting. Emend is used in patients aged from 6 months to prevent nausea and vomiting caused by chemotherapy (medicines used to treat cancer).
EMEND is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The recommended dose is 125 mg orally once daily one hour before start of chemotherapy on Day 1 and 80 mg orally once daily on Days 2 and 3 in the morning.
EMEND należy przyjmować przez 3 dni w skojarzeniu z kortykosteroidem i antagonistą receptora 5-HT3. Zalecana dawka wynosi 125 mg, raz na dobę, podana doustnie na godzinę przed rozpoczęciem chemioterapii w 1. dniu oraz dawka 80 mg, raz na dobę, podana doustnie rano w 2. i 3. dniu.
Zapobieganie nudnościom i wymiotom związanym z przeciwnowotworową chemioterapią o wysokim i umiarkowanym ryzyku wymiotów u dorosłych i młodzieży w wieku od 12 lat. EMEND 125 mg/80 mg stosuje się w leczeniu skojarzonym (patrz punkt 4.2).
What the medication is used for: EMEND®, in combination with 5-HT3 antagonists and dexamethasone, is indicated for the prevention of nausea and vomiting associated with your cancer chemotherapy treatment.
The European Medicines Agency (EMA) makes guidance and templates available to provide marketing authorisation applicants with practical advice on how to draw up the product information for human medicines, which includes the summary of product characteristics, labelling and package leaflet.
tests during treatment with EMEND, - antibiotics to treat infections – such as rifampicin, clarithromycin, telithromycin, - phenytoin - for fits (seizures),
